New hope for kidney cancer patients with bone spread: drug combo trial launches

NCT ID NCT07043608

First seen Jun 24, 2026 · Last updated Jul 28, 2026 · Updated 4 times

Summary

This phase 2 trial tests a new drug called zanzalintinib, taken as a pill, combined with a bone-strengthening agent for people with advanced kidney cancer that has spread to the bones. The study enrolls 20 participants whose cancer has worsened after 1–3 prior treatments, including immunotherapy. The main goal is to see how many patients have no cancer growth after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Zanzalintinib (a targeted therapy pill) plus a bone-strengthening agent (bisphosphonate or denosumab)
What this could lead to
If it works, this could offer a new treatment option for people with kidney cancer that has spread to the bones and has stopped responding to immunotherapy.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The drug may not slow the cancer or could cause side effects like fatigue or bone pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE METASTASES OF A MALIGNANT TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.